Seroprevalence and Demographic Distribution of Blood-Borne Viral Infections among Hemodialysis Patients in Sudan: A Multicenter Study from Conflict-Affected Khartoum State Authors: Ayman Azhary, Alaa Mohammed, Mihad Almomen, Nooh Mohamed Hajhamed, Mogeeb Kabashi, Esra Abdallah Abdalwahed Mahgoub, Claude Mambo Muvunyi, Mawahib Ahmed, Basmah F Alharbi, Emmanuel Edwar Siddig Published: 2026 ABSTRACT AbstractBackgroundBlood-borne viral infections pose considerable health challenges to patients undergoing hemodialysis. This multicenter study evaluated the prevalence and demographic distribution of hepatitis B, hepatitis C, and HIV infections among hemodialysis patients.MethodsThis retrospective cross-sectional study included 940 hemodialysis patients from fifteen facilities in Khartoum State, Sudan from July 2025 to November 2025. The outcomes of the serological tests for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (anti-HCV) antibodies, and anti-HIV antibodies, conducted via standard enzyme-linked immunosorbent assay (ELISA) test, were acquired from the Public Health Laboratory (PHL), Khartoum State. Data was analyzed with R software (version 4.4.2).ResultsThe overall prevalence rates were 7.1% for HBsAg, 12.2% for anti-HCV, and 0.6% for HIV. The prevalence of hepatitis C virus (HCV) exhibited significant variability across dialysis centers (p<0.001), with higher rates observed in certain facilities. No notable correlations between infection status and age or gender were detected. Co-infections were rare.ConclusionsBlood-borne viral infections persist as a significant issue in Sudanese hemodialysis facilities, emphasizing the imperative for consistent infection control measures such as routine blood screening for transfusion. Targeted interventions at high-prevalence centers are essential for decreasing transmission and enhancing patient outcomes.Trial registrationNot applicable.Keywords: Hemodialysis, Blood-Borne Infections, Hepatitis B, Hepatitis C, HIV, Epidemiology Introduction Hemodialysis (HD) is a critical, life-sustaining treatment used to clean the blood in patients with end-stage renal disease (ESRD) who have exhausted all other therapeutic options [1]. Despite its vital role in prolonging life, this procedure, along with disturbances in both innate and adaptive immune responses, significantly increases the vulnerability of HD patients to a wide range of infections. These infectious complications are the foremost cause of disease burden (morbidity) among this population and rank as the second leading cause of mortality, following cardiovascular events. Importantly, the risk of death from cardiovascular causes substantially rises after hospitalization due to infectious episodes [1, 2]. Infections among HD patients predominantly manifest as bacteremia, accounting for the majority of severe cases. The mortality rate from bacteremia in this patient group is remarkably high, estimated to be between 100 and 300 times greater than in the general population. Even when factors such as age, race, sex, diabetes status, and potential errors in record-keeping are taken into account, the risk of death from bacteremia remains about 50 times higher in HD patients compared to individuals in the general population [3–6]. In addition to bacterial infections, the spread of blood-borne viral infections constitutes another major concern within hemodialysis units. Evidence suggests that HD patients are more susceptible than the general population to acquiring various blood-borne viruses. Long-term hemodialysis patients, in particular, appear to be at heightened risk for infections such as hepatitis B virus (HBV) [7–9]. It is estimated that over 257 million people worldwide are chronic carriers of HBV, and annually, more than 880,000 individuals succumb to complications arising from HBV infection [10, 11]. Moreover, other viral pathogens like hepatitis C virus (HCV) and human immunodeficiency virus (HIV) pose significant challenges, especially given the nature of the dialysis process itself, which increases the potential for virus transmission. Consequently, maintaining safety protocols to prevent the spread of these viruses to HD patients and healthcare workers remains an ongoing challenge within hemodialysis units [12, 13]. Given the elevated risk of infection in HD patients and the added complexities of a conflict‑affected setting, contemporary data on the burden of viral infections are essential. Therefore, this study aims to determine the prevalence of HCV, HIV, and HBV among hemodialysis patients at multiple centers in conflict-affected Khartoum State. By establishing this prevalence, we seek to provide evidence that can inform the development of targeted infection control strategies and ultimately improve patient outcomes. Materials and methods Study design, setting, and population We conducted a retrospective cross-sectional study using data from the Public Health Laboratory (PHL), Khartoum State. These patients’ data were compiled from all 15 hemodialysis centers across Khartoum State. Fourteen of these centers are integrated within governmental hospitals and one is a private hospital (Aliaa Hospital). The data of 940 hemodialysis patients whose samples were sent to the Public Health Laboratory (PHL), Khartoum State, for viral testing from July, 2025 to November, 2025 were included in the study, with no exclusion criteria. Data collection An anonymized dataset was obtained from the Public Health Laboratory (PHL), Khartoum State, containing the requested study variables: background data (hemodialysis center, age, gender) and viral screening results (ELISA testing for HIV antibody, HCV antibody, and HBsAg). This data was collected as part of the routine care of hemodialysis patients, as all blood samples for viral screening from these patients must be sent to the Public Health Laboratory (PHL), Khartoum State, for testing, following a standardized procedure. Serological testing was performed using commercially available ELISA kits manufactured by Fortress Diagnostics Ltd (United Kingdom), following the manufacturer’s instructions. The assays employed included: 1/ fourth-generation HCV ELISA kit, used for the detection of antibodies against Hepatitis C Virus (HCV) in human serum or plasma, with a reported specificity of 99.55% and sensitivity of 100%. 2/ third-generation HBsAg ELISA kit, used for the detection of Hepatitis B surface antigen (HBsAg), with a reported specificity of 99.94% and sensitivity of 100%. 3/ fourth-generation HIV ELISA kit, designed for the simultaneous detection of HIV-1 and HIV-2 antibodies as well as HIV p24 antigen, with a reported specificity of 99.75% and sensitivity of 100%. All assays demonstrated high analytical performance as reported by the manufacturer. The HIV 4th-generation assay, in particular, provides enhanced early detection due to its ability to identify both antigen and antibody markers. All study procedures were carried out in accordance with the principles of declaration of Helsinki. Statistical analysis The original dataset (Excel sheet) was cleaned and then analyzed using R software (version 4.4.2) within the RStudio integrated development environment (version 2024.12.1 + 563). The ‘ggplot2’ and ‘dplyr’ packages were utilized for data manipulation and visualization of the results. Descriptive statistics were presented using the median, frequency, and proportions for both demographic and viral screening results. Normality was assessed using the Shapiro-Wilk test. The Mann-Whitney U test, Kruskal-Wallis test, and chi-square test were employed to assess the association between patient characteristics and clinical data. Statistical significance was set at an alpha level of 0.05. Results Patient’s characteristics The study included a total of 940 hemodialysis patients. The age of the patients ranged from 11 to 86 years, with a median of 50 years (IQR = 37–59). Most patients, 437 (46.5%), were between 40 and 59 years, followed by 232 (24.7%) between 20 and 39 years. Two-thirds of the participants were males (66.7%, 627), and females accounted for 313 (33.3%). More than half of the patients were from Al-Nao Hospital (52.4%), followed by Bashaer Hospital (11.4%), Al-Hijra Center (9.4%), and Al-Jazera Eslanj Hospital (8%) (Table 1). Table 1Demographic and clinical characteristics of the study populationCharacteristicFrequencyPercentageAge (Mean ± SD, Median [IQR], Min: Max)47.57 ± 15.35, 50 [37–59], 11:86< 2041(4.3%)20–39 232 (24.7%)40–59437(46.5%)≥ 60230(24.5%) Gender Male627(66.7%)Female313(33.3%) HBs Ag Positive67(7.1%)Negative873(92.9%) HIV Positive6(0.6%)Negative934(99.4%) HCV Positive115(12.2%)Negative825(87.8%) Co-infection HBV/HCV6(0.6%)HIV/HCV2(0.2%) Hemodialysis centers Al-Nao Hospital493(52.4%)Bashaer Hospital107(11.4%)Al-Hjra Center88(9.4%)Al-Jazera Eslanj Hospital76(8%)Al-Kadro Medical Center45 (4.8%)(4.8%)Al-Baan jadeed Hospital38(4%)Al-Fath Hospital32(3.4%)Omdurman Teaching Hospital27(2.9%)Aliaa Hospital13(1.4%)Al-Karama Hospital9(0.95%)Military Hospital5(0.5%)Ombada Hospital3(0.3%)Al-Elofoon Center2(0.2%)Al-Halfaia Hospital1(0.1%)Al-Nahda Medical Center1(0.1%) Demographic and clinical characteristics of the study population Viral screening results Among our participants, 115 patients (12.2%) were reactive for HCV antibodies, 6 patients (0.6%) for HIV antibodies, and 67 patients (7.1%) for HBsAg. Co-infections were observed in eight patients, with HBV/HCV co-infection seen in 6 (0.6%) and HIV/HCV co-infection in 2 (0.2%) patients (Fig. 1). Viral screening results among hemodialysis patients in Khartoum State No significant association was found between the patient’s age and their viral screening results (P > 0.05). HBsAg positivity was slightly higher among females (9%) than males (6.2%), while HCV positivity was higher in males (13.7%) compared to females (9.3%). However, none of the viral markers showed statistically significant differences between males and females (P > 0.05) (Table 2). Table 2Association between viral infection status and demographic characteristics of the study populationHBsAgeP valueHCVP valueHIVP valuePositiveNegativePositiveNegativePositiveNegative Age group < 20 2 (4.9)39 (95.1) 0.07 2 (4.9)39(95.1) 0.29 0 (0)41 (100) 0.88 20–39 20(8.6 )212(91.4)26(11.2)206(88.8)1 (0.4)231 (99.6) 40–59 22 (5.0)415 (95)61 (14)376 (86)3 (0.7)434 (99.3) ≥ 60 23 (10)207 (90)26 (11.3)204(88.7)2 (0.8)228 (99.1) Gender Male 39 (6.2)588(93.8) 0.16 86(13.7)541(86.3) 0.06 5 (0.8)622 (99.2) 0.66 Female 28 (9)285 (91)29 (9.3)284(90.7)1 (0.3)312 (99.7) Hemodialysis Centers Al-Nao Hospital 50(10.1)443(89.9) 0.22 63(12.8)430(87.2) 0.00011 2 (0.4)491 (99.6) 0.85 Bashaer Hospital 6 (5.6)101(94.4)4 (3.7)103(96.3)2 (1.8)105 (98.2) Al-Hjra Center 3 (3.4)85 (96.6)9 (10.3)79 (89.7)0 (0)88 (100) Al-Jazera Eslanj Hospital 2 (2.6)74 (97.4)23(30.7)53 (69.3)0 (0)76 (100) Al-Kadro Medical Center 1 (2.2)44 (97.8)2 (4.4)43 (95.6)0 (0)45 (100) Al-Baan jaded Hospital 2 (5.3)36 (94.7)4 (10.5)34 (89.7)1 (2.6)37 (97.4) Al-Fath Hospital 1 (3.1)31 (96.9)8 (25)24 (75)1 (3.1)31 (96.9) Omdurman Teaching Hospital 2 (7.4)25 (92.6)1 (3.7)26 (96.3)0 (0)27 (100) Aliaa Hospital 0 (0)13 (100)0 (0)13 (100)0 (0)13 (100) Al-Karama Hospital 0 (0)9 (100)0 (0)9 (100)0 (0)9 (100) Military Hospital 0 (0)5 (100)0 (0)5 (100)0 (0)5 (100) Ombada Hospital 0 (0)3(100)1 (33.3)2 (66.7)0 (0)3 (100) Al-Elofoon Center 0 (0)2 (100)0 (0)2 (100)0 (0)2 (100) Al-Halfaia Hospital 0 (0)1 (100)0 (0)1 (100)0 (0)1 (100) Al-Nahda Medical Center 0 (0)1 (100)0 (0)1 (100)0 (0)1 (100) Association between viral infection status and demographic characteristics of the study population Hemodialysis Centers A statistically significant difference in HCV antibody reactivity was observed between different dialysis centers (p < 0.001). The highest rates were observed in Al-Jazera Eslanj (30.7%), Al-Fath (25%), and Al-Nao Hospitals (12.8%). However, no similar difference was seen in HBV or HIV screening results (p > 0.05) (Table 2). Figure 2 (A–C) compares the age distribution between genders for each infection. The boxplots show similar age patterns among male and female patients for HBV (Fig. 2A), HCV (Fig. 2B), and HIV (Fig. 2C), consistent with the lack of statistically significant differences between gender and infection status observed in Table 2. Box plots elucidating the comparison of age distribution between genders according to 2 A: HBV, 2B: HCV, and 2 C: HIV Discussion This study provides a comprehensive assessment of the prevalence of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infections among patients undergoing haemodialysis in conflict-affected Khartoum State. The results reveal important patterns and highlight persistent obstacles related to infection prevention in dialysis environments. The prevalence of HBsAg among the HD patients in this study was 7.1%. A result consistent with the global pooled prevalence of 7.32% in HD patient cohorts [14]. However, this rate was lower than the pooled prevalence across HD patients in Africa (9.88%) [15], as well as studies in Iran (13.8%) [16], Ghana (12.4%) [17], and Cameroon (10.6%) [18], but higher than rates reported in Libya (1.14%) [19], and Yemen (5.5%) [20]. This disparity highlights the impact of local factors, such as general population prevalence, healthcare practice standards, the efficacy of infection control measures, and country-specific screening protocols. Nationally, the 7.1% figure is significantly higher than the 4.3% hepatitis B prevalence among the Sudanese general population in 2022, representing a 65% relative increase [21], reaffirming the high vulnerability of dialysis patients to HBV infection. Further, it exceeds data from earlier studies conducted approximately a decade ago, which reported lower rates of 6% at the Rabat University Hospital, Morocco [22] and 4.5% [23]. The increase in prevalence, in addition to standard study variations, suggests a concerning trend potentially associated with the cumulative decline of the Sudanese health system over the past decade [24].This situation has been acutely aggravated by the recent 2023 conflict, which has caused widespread infrastructural damage, service disruption, and supply chain failures, severely compromising the maintenance of quality clinical care in HD centers [25]. In parallel, our study demonstrated an HCV antibody positivity rate of 12.2%, which is higher than the rates reported in Yemen (7.3%) [20], Iran (4.6%) [16], Ghana (6.7%) [17], Somalia (3.2%) [26], and Libya (1.14%) [19], implying similar local contributing factors mentioned above. In Sudan, this rate notably surpasses the 1.10% prevalence observed in the general population in 2022 [21], and exceeds the 8.5% rate reported by Gasim et al. [23]. This echoes the trend observed with HCV. However, our rate is far lower than the global meta-analytical estimates for hemodialysis populations that range from 20.7% to 24.3% [27]. This finding suggests that current local infection control measures in Sudanese hemodialysis centers, although inadequate to prevent all new infections, provide some mitigating effect relative to the most severely impacted global centers. HIV infection was identified in 0.6% of the study population, consistent with the lower prevalence noted in comparable groups. A systematic review and meta-analysis indicated that the global pooled prevalence of HIV among dialysis patients is roughly 0.8% [28]. However, the rate is still threefold higher than the national adult prevalence of HIV in Sudan in 2020, which was 0.2% [29]. The demographic data reveal that the majority of patients are middle-aged, with a mean age of approximately 48 years, and a slight male predominance. Age and gender exhibited no statistically significant associations with the prevalence of HBV, HCV, or HIV, indicating that viral infections are prevalent across various demographic groups in this context. Consequently, hepatitis control measures must be universal, applying to all patients receiving hemodialysis. A notable finding is the substantial variation in HCV prevalence among various hemodialysis centers (p<0.001). Hospitals like Al-Jazera Eslanj and Al-Fath exhibited elevated infection rates relative to others, potentially indicating variations in infection control practices, patient management, or environmental factors across the centers. These variations require specific interventions to standardize safety measures across all facilities. Future research should evaluate the factors contributing to the variation in rates among these centers, and clinical audits may be applied to ensure the effective implementation of infection control measures aimed at reducing transfusion-transmitted infections (TTIs). The heightened prevalence of both HBV and HCV, in comparison to national and historical local HD data, underscores the urgent need for targeted interventions, including (1) establishing a mandatory screening program for HBV, HCV, and HIV for all HD patients with linkage to confirmatory testing; (2) implementing a dedicated isolation protocol for HBsAg-positive patients, including assignment to designated dialysis machines in a separate room or dedicated shift; (3) wearing disposable gloves when caring for the patient or touching the patient’s equipment at the dialysis station; and (4) introducing a hepatitis B vaccination program for susceptible dialysis-dependent patients using a 40 µg booster dose [30]. Even before the 2023 war, the health system in Sudan was facing a significant systemic deficiency that hindered effective viral hepatitis control in the country. This includes the weak, underfunded national hepatitis control program, lack of viral hepatitis policies and guidelines, lack of a hepatitis surveillance system, inadequate diagnostic (particularly insufficient screening capacity for transfusion-transmissible infections (TTIs) with inconsistent availability of enzyme immunoassay (EIA) kits and lack of nucleic acid testing (NAT) for window period detection) and treatment services across public health facilities, lack of a clear referral pathway for patients with hepatitis-positive patients, and the lack of baseline data for the implementation of single-use or safety-engineered devices [29]. While the National Hepatitis Strategic Plan (2019–2025) of Sudan offered a step forward, specifically by integrating HBV vaccination and testing programs for HD patients [29], its implementation was challenged by the political instability of the country and then the 2023 war. The conflict has accelerated the collapse of clinical quality by driving poor infection control through severe resource shortages, workforce displacement, overcrowding, supply chain disruptions, and infrastructural damage [31, 32]. This puts HD patients at greater risk of infections. The Federal Ministry of Health, the World Health Organization (WHO), the Salman Humanitarian Aid and Relief Center, and the Qatari government are all working together to reopen dialysis centers in Sudan by supplying the machines, supplies, and infrastructure required [33]. This effort must be accompanied by strict enforcement of standardized infection control measures to ensure patient safety. These goals can be achieved through the following specific actions: (1) designating an infection prevention and control (IPC) focal person at each dialysis center responsible for daily monitoring and reporting; (2) conducting monthly supervisory visits with standardized IPC audit checklists to assess compliance with hand hygiene, equipment disinfection, and waste management protocols; (3) implementing a mandatory biannual training program for all HD staff covering standard precautions, blood-borne pathogen transmission risks, and outbreak response; (4) establishing a centralized procurement and supply chain system to ensure uninterrupted availability of single-use dialyzers, bloodlines, needles, and personal protective equipment; and (5) introducing safety-engineered devices, such as retractable needles and needleless connectors, to reduce needlestick injuries among healthcare workers [30, 34]. Strengths of this study include: 1/ large sample size (n = 940), 2/ multicenter coverage (15 facilities), 3/ real-world data from a conflict zone, and 4/ identifies center-level heterogeneity. Despite the valuable insights offered, the study has limitations. The cross-sectional design provides a snapshot but cannot establish causality or temporal trends. Further longitudinal studies are warranted to monitor infection dynamics over time and evaluate the impact of implemented intervention strategies. Furthermore, expanding testing to include other markers like genotyping and viral loads could result in a deeper understanding of infection patterns and transmission channels. The use of secondary data limited the study’s scope to the available information; therefore, future studies can explore factors related to patients and institutions that may affect infection rates. Despite these limitations, our study provides valuable and current information on the TTIs among HD patients, offering a crucial baseline for guiding immediate public health interventions in conflict-affected Sudan. Conclusions The findings emphasize the persistent challenge of managing blood-borne viral infections among hemodialysis patients. Standardized infection control measures, routine screening, vaccination programs (where applicable), clear referral pathways for hepatitis and HIV-positive patients and education are essential to reduce infection rates. Regular audits and targeted interventions in centers with higher infection prevalence could significantly improve patient safety and outcomes. Ultimately, a multi-faceted approach integrating policy, clinical practice, and patient education is pivotal in tackling these infections in dialysis settings. Acknowledgements Not applicable. Author contributions A.A and E.E.S. Conceived the study. A.M and M.A (Mihad Almomen). Performed the data collection and laboratory work. N.M.H. Performed the data visualization and analysis. E.E.S, A.A, and E.A.A.M. Writing – original draft. A.A, M.A (Mawahib Ahmed), M.K, B.F.A and C.M.M. Writing—review & editing. All the authors read and approved the final manuscript. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Data availability The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was conducted in accordance with ethical guidelines for retrospective research. Patient confidentiality was maintained by anonymizing all data. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Ayman Azhary, Email: azhryaymn18@gmail.com. Mihad Almomen, Email: mihadalmomen@gmail.com. References Associated Data Data Availability Statement The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.